These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17187506)

  • 1. HIV and pharmacogenomics in 2007.
    Khoo S
    Pharmacogenomics; 2007 Jan; 8(1):25-7. PubMed ID: 17187506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
    Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
    Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS].
    Cholewińska G
    Przegl Epidemiol; 2008; 62(1):149-54. PubMed ID: 18536238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee.
    Gazzard B; Moyle G
    Lancet; 1998 Jul; 352(9124):314-6. PubMed ID: 9690427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy.
    Pozniak A; Gazzard B; Anderson J; Babiker A; Churchill D; Collins S; Fisher M; Johnson M; Khoo S; Leen C; Loveday C; Moyle G; Nelson M; Peter B; Phillips A; Pillay D; Wilkins E; Williams I; Youle M;
    HIV Med; 2003 Oct; 4 Suppl 1():1-41. PubMed ID: 14511246
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases.
    Haas DW; Kuritzkes DR; Ritchie MD; Amur S; Gage BF; Maartens G; Masys D; Fellay J; Phillips E; Ribaudo HJ; Freedberg KA; Petropoulos C; Manolio TA; Gulick RM; Haubrich R; Kim P; Dehlinger M; Abebe R; Telenti A;
    HIV Clin Trials; 2011; 12(5):277-85. PubMed ID: 22180526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring.
    Flexner CW
    Top HIV Med; 2003; 11(2):40-4. PubMed ID: 12717040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
    Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
    J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy.
    Deminie CA; Bechtold CM; Riccardi K; Rose RE; Samanta H; Lin PF; Colonno RJ
    AIDS; 1998 Jan; 12(1):110-2. PubMed ID: 9456262
    [No Abstract]   [Full Text] [Related]  

  • 11. [Saving on drugs, reducing side-effects. Treatment interruptions benefit acute and chronic HIV infected patients].
    Jäger H
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():8-11. PubMed ID: 12043085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of the drug resistance mutations in HIV-1: 2007.
    Johnson VA; Brun-Vézinet F; Clotet B; Günthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
    Top HIV Med; 2007; 15(4):119-25. PubMed ID: 17720996
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacogenomics and the prevention of mother-to-child transmission of HIV.
    Cressey TR; Lallemant M
    Pharmacogenomics; 2010 Jan; 11(1):1-4. PubMed ID: 20017665
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiretroviral drug resistance--implications for HIV/AIDS reduction in sub-Saharan Africa and other developing countries.
    Obiako OR; Murktar HM; Ogoina D
    Niger J Med; 2010; 19(4):352-60. PubMed ID: 21526620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to antiretroviral drugs in newly diagnosed, young treatment-naïve HIV-positive pregnant women in the province of KwaZulu-Natal, South Africa.
    Parboosing R; Naidoo A; Gordon M; Taylor M; Vella V
    J Med Virol; 2011 Sep; 83(9):1508-13. PubMed ID: 21739439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical implications of antiretroviral pharmacogenomics.
    Fox J; Boffito M; Winston A
    Pharmacogenomics; 2006 Jun; 7(4):587-96. PubMed ID: 16753006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of access to HIV treatment.
    Galatowitsch P; Siegfried N
    Science; 2006 Dec; 314(5805):1540-1; author reply 1540-1. PubMed ID: 17158305
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of Viroseq-HIV version 2 for HIV drug resistance.
    Mukaide M; Sugiura W; Matuda M; Usuku S; Noguchi Y; Suzuki K; Kawata K; Ito A; Sagara H; Yamada K; Kondo M; Imai M
    Jpn J Infect Dis; 2000 Oct; 53(5):203-5. PubMed ID: 11135705
    [No Abstract]   [Full Text] [Related]  

  • 19. Overview on HIV-1-related drug resistance: from theory to clinical practice.
    Moroni M; Balotta C; Rusconi S
    J Biol Regul Homeost Agents; 1998; 12(1-2 Suppl):15-8. PubMed ID: 9689573
    [No Abstract]   [Full Text] [Related]  

  • 20. Your next nightmare: 28% of new HIV cases may be drug-resistant.
    AIDS Alert; 1999 Dec; 14(12):133-7. PubMed ID: 11366987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.